Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR128 in advanced solid tumors
NCT05751356Phase 1Recruiting
- Sponsor
- Tarapeutics Science Inc
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TR128 in solid tumor, sponsored by Tarapeutics Science Inc. Primary endpoints: Adverse Events and Serious Adverse Events, Dose Limited Toxicities and 2 more. Started Feb 2024; status: recruiting.
02
Drugs
TR128
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05751356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751356.